Skip to content

A Comparison of Contact Aspiration Versus Stent Retriever for Acute Basilar Artery Occlusion

A Comparison of Contact Aspiration Versus Stent Retriever for Acute Basilar Artery Occlusion: A Multicentre, Prospective, Open-label, Blind Endpoint, Randomized Controlled Trial

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05615038
Acronym
ANGEL-COAST
Enrollment
338
Registered
2022-11-14
Start date
2022-11-07
Completion date
2025-06-30
Last updated
2025-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Basilar Artery Occlusion, Endovascular Treatment

Brief summary

Compare the effectiveness and safety of contact aspiration (CA) and stent retriever (SR) in acute ischemic stroke patients with basilar artery occlusion.

Interventions

Contant aspiration is an approach that utilizes the advantages of large-bore aspiration catheters that can be easily tracked and introduced into the cerebral circulation to directly remove the thrombus via negative pressure aspiration.

Stent retriever thrombetomy is an approach that utilize sself-expandable stent for thrombectomy. The stent retriever is expanded to capture the thrombus, which immediately may restore blood flow.

Sponsors

Beijing Tiantan Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age≥18 years; 2. Acute basilar artery occlusion confirmed by CTA/MRA/DSA; 3. Last known well to puncture time≤24 hours; 4. pc-ASPECTS score≥6 points; 5. Baseline NIHSS score≥10 points; 6. Consent to endovascular treatment; 7. Informed consent signed. Clinical

Exclusion criteria

1. Baseline mRS≥3 points; 2. Known or suspected severe basilar artery stenosis (\>70%) or chronic occlusion based on history, imaging, or clinical manifestations; 3. Refractory hypertension that is difficult to be controlled by drugs (defined as persistent systolic blood pressure \>185 mmHg or diastolic blood pressure \>110 mmHg) 4. Genetic or acquired hemorrhagic tendency, coagulation factor deficiency or on anticoagulant therapy and International Normalized Ratio (INR) \> 3.0; 5. Laboratory tests: baseline blood glucose \<50mg/dl (2.8mmol/L) or \>400mg/dl (22.2mmol/L); Baseline platelet count \<50×109/L; 6. Known severe allergy (more severe than skin rash) to contrast agents uncontrolled by medications; 7. Females who are pregnant, or those of childbearing, potential with positive urine or serum beta Human Chorionic Gonadotropin test; 8. Other circumstances that the investigator considers inappropriate for participation in the trial or that may pose significant risks to patients (such as inability to understand and/or follow the study procedures and/or follow up due to mental disorders, cognitive or emotional disorders). Imaging

Design outcomes

Primary

MeasureTime frameDescription
Rate of first pass effect (FPE)24 hours\[The definition of FPE: 1) single pass/use of the device; 2)recanalization of the large vessel occlusion to eTICI 2C/3;3) no use of rescue therapy.\]

Secondary

MeasureTime frameDescription
All cause of mortality at 90±14 days90 days
Rate of complete reperfusion (eTICI 3) after first-line thrombectomy strategy and at the end of endovascular procedure24 hourseTICI: grade 0: no perfusion noted (0% reperfusion) grade 1: reduction in thrombus but without any resultant filling of distal arterial branches grade 2 grade 2a: reperfusion of 1-49% of the territory grade 2b50: reperfusion of 50-66% of the territory grade 2b67: reperfusion of 67-89% of the territory grade 2c: extensive reperfusion of 90-99% of the territory grade 3: complete or full reperfusion (100% reperfusion)
Rate of near to complete reperfusion (eTICI 2c/3) after first-line thrombectomy strategy and at the end of endovascular procedure24 hourseTICI: grade 0: no perfusion noted (0% reperfusion) grade 1: reduction in thrombus but without any resultant filling of distal arterial branches grade 2 grade 2a: reperfusion of 1-49% of the territory grade 2b50: reperfusion of 50-66% of the territory grade 2b67: reperfusion of 67-89% of the territory grade 2c: extensive reperfusion of 90-99% of the territory grade 3: complete or full reperfusion (100% reperfusion)
Rate of successful reperfusion (eTICI 2b/2c/3) after first-line thrombectomy strategy and at the end of endovascular procedure24 hourseTICI: grade 0: no perfusion noted (0% reperfusion) grade 1: reduction in thrombus but without any resultant filling of distal arterial branches grade 2 grade 2a: reperfusion of 1-49% of the territory grade 2b50: reperfusion of 50-66% of the territory grade 2b67: reperfusion of 67-89% of the territory grade 2c: extensive reperfusion of 90-99% of the territory grade 3: complete or full reperfusion (100% reperfusion)
Rate of Arterial Occlusive Lesion (AOL) recanalization score 3 after first-line thrombectomy strategy and at the end of endovascular procedure24 hoursAOL recanalization score is evaluated between 0 to 3: 0 indicates no recanalization of the primary occlusive lesion; 1. indicates incomplete or partial recanalization of the primary occlusive lesion with no distal flow; 2. indicates incomplete or partial recanalization of the primary occlusive lesion with any distal flow; 3. indicates complete recanalization of the primary occlusive with any distal flow.
Groin puncture time to successful reperfusion time (min)24 hoursevaluated in minutes
The difference of NIHSS score between 24-hour and baseline24 hoursNIHSS (National Institutes of Health Stroke Scale) score is evaluated between 0-42 0 is normal and 42 maximal gravity
Rate of procedure-related complications, included arterial dissection, embolization in a new territory, arterial perforation and subarachnoid haemorrhage24 hours
Rate of mRS 0-1 at at 90±14 days90 daysmRS is evaluated between 0 to 6. A score of 0 indicates that there is no disability and a score of 6 indicates death.
Rate of mRS 0-2 at at 90±14 days90 daysmRS is evaluated between 0 to 6. A score of 0 indicates that there is no disability and a score of 6 indicates death.
Rate of mRS 0-3 at at 90±14 days90 daysmRS is evaluated between 0 to 6. A score of 0 indicates that there is no disability and a score of 6 indicates death.
Quality of life at 90±14 days assessed by EuroQol 5D-5L scale90 daysEuroQol 5D-5L comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
Rate of symptomatic intracranial hemorrhage within 48 hours (according to Heidelberg Bleeding Classification)48 hoursHeidelberg Bleeding Classification: 1. Hemorrhagic transformation of infarcted brain tissue 1a HI1 Scattered small petechiae, no mass effect 1b HI2 Confluent petechiae, no mass effect 1c PH1 Hematoma within infarcted tissue, occupying \<30%, no substantive mass effect 2 Intracerebral hemorrhage within and beyond infarcted brain tissue PH2 Hematoma occupying 30% or more of the infarcted tissue, with obvious mass effect 3 Intracerebral hemorrhage outside the infarcted brain tissue or intracranial-extracerebral hemorrhage 3a Parenchymal hematoma remote from infarcted brain tissue 3b Intraventricular hemorrhage 3c Subarachnoid hemorrhage 3d Subdural hemorrhage
Rate of any intracranial hemorrhage within 48 hours (according to Heidelberg Bleeding Classification)48 hoursHeidelberg Bleeding Classification: 1. Hemorrhagic transformation of infarcted brain tissue 1a HI1 Scattered small petechiae, no mass effect 1b HI2 Confluent petechiae, no mass effect 1c PH1 Hematoma within infarcted tissue, occupying \<30%, no substantive mass effect 2 Intracerebral hemorrhage within and beyond infarcted brain tissue PH2 Hematoma occupying 30% or more of the infarcted tissue, with obvious mass effect 3 Intracerebral hemorrhage outside the infarcted brain tissue or intracranial-extracerebral hemorrhage 3a Parenchymal hematoma remote from infarcted brain tissue 3b Intraventricular hemorrhage 3c Subarachnoid hemorrhage 3d Subdural hemorrhage
Modified Rankin Score (mRS) at 90±14 days (shift analysis)90 daysmRS is evaluated between 0 to 6. A score of 0 indicates that there is no disability and a score of 6 indicates death.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026